A Novel Temozolomide-Myricetin Drug-Drug Cocrystal: Preparation, Characterization, Property Evaluations

Objectives: Drug-drug cocrystals with improved properties can be used to facilitate the development of synergistic therapeutic combinations. The goal of the present study is to obtain novel drug-drug cocrystals involving two anti-glioma agents, temozolomide (TMZ) and myricetin (MYR). Methods: The no...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutics Vol. 17; no. 7; p. 906
Main Authors Qin, Hai-Xin, Wang, Jie, Peng, Jia-Hui, Dai, Xia-Lin, Li, Cai-Wen, Lu, Tong-Bu, Chen, Jia-Mei
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 13.07.2025
MDPI
Subjects
Crystal structure
Crystals
Data collection
Diffraction
Drug therapy
drug-drug cocrystal
Drugs
Flavonoids
Fourier transforms
Glioma
Gliomas
Health aspects
Humidity
Hydrogen
Hydrogen bonding
Infrared spectroscopy
myricetin
Pharmaceuticals
Physicochemical properties
Radiation
Software
Spectrum analysis
stability
Structure
tabletability
Temozolomide
X-rays
China
Germany
Tianjin China
Shanghai China
temozolomide
myricetin
tabletability
drug-drug cocrystal
dissolution
crystal structure
stability
Online AccessGet full text

Cover

Abstract Objectives: Drug-drug cocrystals with improved properties can be used to facilitate the development of synergistic therapeutic combinations. The goal of the present study is to obtain novel drug-drug cocrystals involving two anti-glioma agents, temozolomide (TMZ) and myricetin (MYR). Methods: The novel TMZ-MYR cocrystal was prepared via slurry and solvent evaporation techniques and characterized by X-ray diffraction, thermal analysis, infrared spectroscopy, and dynamic vapor sorption measurements. The stability, compaction, and dissolution properties were also evaluated. Results: Crystal structure analysis revealed that the cocrystal lattice contains two TMZ molecules, one MYR molecule, and four water molecules, which are linked by hydrogen bonding interactions to produce a three-dimensional network. The cocrystal hydrate exhibited favorable stability and tabletability compared to pure TMZ. A dissolution study showed that the maximum solubility of MYR in the cocrystal (176.4 μg/mL) was approximately 6.6 times higher than that of pure MYR·H2O (26.9 μg/mL), while the solubility of TMZ from the cocrystal (786.7 µg/mL) was remarkably lower than that of pure TMZ (7519.8 µg/mL). The solubility difference between MYR and TMZ was diminished from ~280-fold to ~4.5-fold. Conclusions: Overall, the TMZ-MYR cocrystal optimizes the stability and tabletability of TMZ and the dissolution behavior of both drugs, offering a promising approach for synergistic anti-glioma therapy with improved clinical potential.
AbstractList Objectives: Drug-drug cocrystals with improved properties can be used to facilitate the development of synergistic therapeutic combinations. The goal of the present study is to obtain novel drug-drug cocrystals involving two anti-glioma agents, temozolomide (TMZ) and myricetin (MYR). Methods: The novel TMZ-MYR cocrystal was prepared via slurry and solvent evaporation techniques and characterized by X-ray diffraction, thermal analysis, infrared spectroscopy, and dynamic vapor sorption measurements. The stability, compaction, and dissolution properties were also evaluated. Results: Crystal structure analysis revealed that the cocrystal lattice contains two TMZ molecules, one MYR molecule, and four water molecules, which are linked by hydrogen bonding interactions to produce a three-dimensional network. The cocrystal hydrate exhibited favorable stability and tabletability compared to pure TMZ. A dissolution study showed that the maximum solubility of MYR in the cocrystal (176.4 μg/mL) was approximately 6.6 times higher than that of pure MYR·H2O (26.9 μg/mL), while the solubility of TMZ from the cocrystal (786.7 µg/mL) was remarkably lower than that of pure TMZ (7519.8 µg/mL). The solubility difference between MYR and TMZ was diminished from ~280-fold to ~4.5-fold. Conclusions: Overall, the TMZ-MYR cocrystal optimizes the stability and tabletability of TMZ and the dissolution behavior of both drugs, offering a promising approach for synergistic anti-glioma therapy with improved clinical potential.
Objectives: Drug-drug cocrystals with improved properties can be used to facilitate the development of synergistic therapeutic combinations. The goal of the present study is to obtain novel drug-drug cocrystals involving two anti-glioma agents, temozolomide (TMZ) and myricetin (MYR). Methods: The novel TMZ-MYR cocrystal was prepared via slurry and solvent evaporation techniques and characterized by X-ray diffraction, thermal analysis, infrared spectroscopy, and dynamic vapor sorption measurements. The stability, compaction, and dissolution properties were also evaluated. Results: Crystal structure analysis revealed that the cocrystal lattice contains two TMZ molecules, one MYR molecule, and four water molecules, which are linked by hydrogen bonding interactions to produce a three-dimensional network. The cocrystal hydrate exhibited favorable stability and tabletability compared to pure TMZ. A dissolution study showed that the maximum solubility of MYR in the cocrystal (176.4 μg/mL) was approximately 6.6 times higher than that of pure MYR·H2O (26.9 μg/mL), while the solubility of TMZ from the cocrystal (786.7 µg/mL) was remarkably lower than that of pure TMZ (7519.8 µg/mL). The solubility difference between MYR and TMZ was diminished from ~280-fold to ~4.5-fold. Conclusions: Overall, the TMZ-MYR cocrystal optimizes the stability and tabletability of TMZ and the dissolution behavior of both drugs, offering a promising approach for synergistic anti-glioma therapy with improved clinical potential.Objectives: Drug-drug cocrystals with improved properties can be used to facilitate the development of synergistic therapeutic combinations. The goal of the present study is to obtain novel drug-drug cocrystals involving two anti-glioma agents, temozolomide (TMZ) and myricetin (MYR). Methods: The novel TMZ-MYR cocrystal was prepared via slurry and solvent evaporation techniques and characterized by X-ray diffraction, thermal analysis, infrared spectroscopy, and dynamic vapor sorption measurements. The stability, compaction, and dissolution properties were also evaluated. Results: Crystal structure analysis revealed that the cocrystal lattice contains two TMZ molecules, one MYR molecule, and four water molecules, which are linked by hydrogen bonding interactions to produce a three-dimensional network. The cocrystal hydrate exhibited favorable stability and tabletability compared to pure TMZ. A dissolution study showed that the maximum solubility of MYR in the cocrystal (176.4 μg/mL) was approximately 6.6 times higher than that of pure MYR·H2O (26.9 μg/mL), while the solubility of TMZ from the cocrystal (786.7 µg/mL) was remarkably lower than that of pure TMZ (7519.8 µg/mL). The solubility difference between MYR and TMZ was diminished from ~280-fold to ~4.5-fold. Conclusions: Overall, the TMZ-MYR cocrystal optimizes the stability and tabletability of TMZ and the dissolution behavior of both drugs, offering a promising approach for synergistic anti-glioma therapy with improved clinical potential.
Objectives: Drug-drug cocrystals with improved properties can be used to facilitate the development of synergistic therapeutic combinations. The goal of the present study is to obtain novel drug-drug cocrystals involving two anti-glioma agents, temozolomide (TMZ) and myricetin (MYR). Methods: The novel TMZ-MYR cocrystal was prepared via slurry and solvent evaporation techniques and characterized by X-ray diffraction, thermal analysis, infrared spectroscopy, and dynamic vapor sorption measurements. The stability, compaction, and dissolution properties were also evaluated. Results: Crystal structure analysis revealed that the cocrystal lattice contains two TMZ molecules, one MYR molecule, and four water molecules, which are linked by hydrogen bonding interactions to produce a three-dimensional network. The cocrystal hydrate exhibited favorable stability and tabletability compared to pure TMZ. A dissolution study showed that the maximum solubility of MYR in the cocrystal (176.4 μg/mL) was approximately 6.6 times higher than that of pure MYR·H[sub.2]O (26.9 μg/mL), while the solubility of TMZ from the cocrystal (786.7 µg/mL) was remarkably lower than that of pure TMZ (7519.8 µg/mL). The solubility difference between MYR and TMZ was diminished from ~280-fold to ~4.5-fold. Conclusions: Overall, the TMZ-MYR cocrystal optimizes the stability and tabletability of TMZ and the dissolution behavior of both drugs, offering a promising approach for synergistic anti-glioma therapy with improved clinical potential.
: Drug-drug cocrystals with improved properties can be used to facilitate the development of synergistic therapeutic combinations. The goal of the present study is to obtain novel drug-drug cocrystals involving two anti-glioma agents, temozolomide (TMZ) and myricetin (MYR). : The novel TMZ-MYR cocrystal was prepared via slurry and solvent evaporation techniques and characterized by X-ray diffraction, thermal analysis, infrared spectroscopy, and dynamic vapor sorption measurements. The stability, compaction, and dissolution properties were also evaluated. : Crystal structure analysis revealed that the cocrystal lattice contains two TMZ molecules, one MYR molecule, and four water molecules, which are linked by hydrogen bonding interactions to produce a three-dimensional network. The cocrystal hydrate exhibited favorable stability and tabletability compared to pure TMZ. A dissolution study showed that the maximum solubility of MYR in the cocrystal (176.4 μg/mL) was approximately 6.6 times higher than that of pure MYR·H O (26.9 μg/mL), while the solubility of TMZ from the cocrystal (786.7 µg/mL) was remarkably lower than that of pure TMZ (7519.8 µg/mL). The solubility difference between MYR and TMZ was diminished from ~280-fold to ~4.5-fold. : Overall, the TMZ-MYR cocrystal optimizes the stability and tabletability of TMZ and the dissolution behavior of both drugs, offering a promising approach for synergistic anti-glioma therapy with improved clinical potential.
Objectives : Drug-drug cocrystals with improved properties can be used to facilitate the development of synergistic therapeutic combinations. The goal of the present study is to obtain novel drug-drug cocrystals involving two anti-glioma agents, temozolomide (TMZ) and myricetin (MYR). Methods : The novel TMZ-MYR cocrystal was prepared via slurry and solvent evaporation techniques and characterized by X-ray diffraction, thermal analysis, infrared spectroscopy, and dynamic vapor sorption measurements. The stability, compaction, and dissolution properties were also evaluated. Results : Crystal structure analysis revealed that the cocrystal lattice contains two TMZ molecules, one MYR molecule, and four water molecules, which are linked by hydrogen bonding interactions to produce a three-dimensional network. The cocrystal hydrate exhibited favorable stability and tabletability compared to pure TMZ. A dissolution study showed that the maximum solubility of MYR in the cocrystal (176.4 μg/mL) was approximately 6.6 times higher than that of pure MYR·H 2 O (26.9 μg/mL), while the solubility of TMZ from the cocrystal (786.7 µg/mL) was remarkably lower than that of pure TMZ (7519.8 µg/mL). The solubility difference between MYR and TMZ was diminished from ~280-fold to ~4.5-fold. Conclusions : Overall, the TMZ-MYR cocrystal optimizes the stability and tabletability of TMZ and the dissolution behavior of both drugs, offering a promising approach for synergistic anti-glioma therapy with improved clinical potential.
Audience Academic
Author Peng, Jia-Hui
Qin, Hai-Xin
Dai, Xia-Lin
Chen, Jia-Mei
Lu, Tong-Bu
Wang, Jie
Li, Cai-Wen
AuthorAffiliation 1 School of Chemistry and Chemical Engineering, Tianjin University of Technology, Tianjin 300384, China; qinhaixin928@163.com (H.-X.Q.); pengjiahui@stud.tjut.edu.cn (J.-H.P.); daixialin@email.tjut.edu.cn (X.-L.D.)
3 Institute for New Energy Materials and Low Carbon Technologies, School of Materials Science and Engineering, Tianjin University of Technology, Tianjin 300384, China; lutongbu@tjut.edu.cn
2 Bionna (Beijing) Medicine Technology Co., Ltd., Beijing 102600, China; wangjie199707w@163.com
AuthorAffiliation_xml – name: 3 Institute for New Energy Materials and Low Carbon Technologies, School of Materials Science and Engineering, Tianjin University of Technology, Tianjin 300384, China; lutongbu@tjut.edu.cn
– name: 1 School of Chemistry and Chemical Engineering, Tianjin University of Technology, Tianjin 300384, China; qinhaixin928@163.com (H.-X.Q.); pengjiahui@stud.tjut.edu.cn (J.-H.P.); daixialin@email.tjut.edu.cn (X.-L.D.)
– name: 2 Bionna (Beijing) Medicine Technology Co., Ltd., Beijing 102600, China; wangjie199707w@163.com
Author_xml – sequence: 1
  givenname: Hai-Xin
  surname: Qin
  fullname: Qin, Hai-Xin
– sequence: 2
  givenname: Jie
  surname: Wang
  fullname: Wang, Jie
– sequence: 3
  givenname: Jia-Hui
  surname: Peng
  fullname: Peng, Jia-Hui
– sequence: 4
  givenname: Xia-Lin
  surname: Dai
  fullname: Dai, Xia-Lin
– sequence: 5
  givenname: Cai-Wen
  surname: Li
  fullname: Li, Cai-Wen
– sequence: 6
  givenname: Tong-Bu
  surname: Lu
  fullname: Lu, Tong-Bu
– sequence: 7
  givenname: Jia-Mei
  surname: Chen
  fullname: Chen, Jia-Mei
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40733114$$D View this record in MEDLINE/PubMed
BookMark eNptkt9v0zAQxy00xEbZnwCKxAsPZJxju455QVXZYNKAPYxn6-I4naskLnZSqfvr565lrGi2ZJ_OH3_vh-41Oep9bwl5S-GMMQWfVrcYOjR2HJyJVIIEBdMX5IQqpXKuCnb0xD4mpzEuIS3GaMnUK3LMQSab8hOymGU__dq22Y3t_J1vfedqm__YBGfs4PrsaxgX-fbI5t6ETRyw_ZxdB7vCgIPz_cdsnnJBM9jg7vae6-BXNgyb7HyN7fjgjG_IywbbaE_394T8vji_mX_Pr359u5zPrnLDFB1yIRsjlbJyWghWcVnW0FTYlIoCoKGcCsW5aOpSYKUMTEslRaWUoA3UDHjBJuRyp1t7XOpVcB2Gjfbo9IPDh4XGkLrWWl3RsqDA5JRhxSsBKExRTgUwxVMOqVkT8mWntRqrztbG9kPA9kD08KV3t3rh15oWhVKSiqTwYa8Q_J_RxkF3LhrbtthbP0bNCsYlCAplQt__hy79GPrUqy3FCg5cqn_UAlMFrm98Cmy2onpW8hRUAPBEnT1DpV3bzpk0So1L_oMP755W-lji3zlJgNgBJvgYg20eEQp6O5L62ZFk97hu1SI
Cites_doi 10.3390/pharmaceutics14010116
10.1021/acs.cgd.8b00807
10.1039/C1CE06278F
10.1007/s13765-016-0150-2
10.1039/B818330A
10.1016/j.ijpharm.2015.12.001
10.1177/09731296231216828
10.1021/cg3002948
10.1016/j.drudis.2016.02.001
10.1093/neuonc/noy072
10.1021/cg5018642
10.1166/asl.2017.8486
10.1016/j.ejps.2017.04.008
10.3390/molecules181215344
10.1016/j.ijpharm.2012.10.043
10.2174/1871527317666180611090006
10.1016/j.apsb.2018.09.008
10.1016/j.neulet.2009.03.031
10.1039/c000614a
10.1016/j.ijpharm.2023.123497
10.1007/s11060-015-1804-3
10.1021/cg900129f
10.3390/pharmaceutics17050678
10.1021/mp070001z
10.1080/01635581.2019.1638424
10.1016/j.molstruc.2017.04.015
10.1200/JCO.1999.17.8.2604
10.1021/jm00096a013
10.1002/asia.201200205
10.1021/acs.cgd.0c01153
10.1007/s10637-020-00979-2
10.1016/j.jconrel.2022.08.024
10.3390/pharmaceutics17030371
ContentType Journal Article
Copyright COPYRIGHT 2025 MDPI AG
2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2025 by the authors. 2025
Copyright_xml – notice: COPYRIGHT 2025 MDPI AG
– notice: 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2025 by the authors. 2025
DBID AAYXX
CITATION
NPM
3V.
7XB
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
GNUQQ
GUQSH
M2O
MBDVC
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.3390/pharmaceutics17070906
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
ProQuest Central (purchase pre-March 2016)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
ProQuest Central Student
ProQuest Research Library
Research Library
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Basic
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest One Academic UKI Edition
ProQuest Central Korea
ProQuest Research Library
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
CrossRef
Publicly Available Content Database

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1999-4923
ExternalDocumentID oai_doaj_org_article_b182103763ab4b50a5c28650394c7903
PMC12299715
A849975004
40733114
10_3390_pharmaceutics17070906
Genre Journal Article
GeographicLocations China
Germany
Tianjin China
Shanghai China
GeographicLocations_xml – name: China
– name: Germany
– name: Tianjin China
– name: Shanghai China
GrantInformation_xml – fundername: National Natural Science Foundation of China
  grantid: 22271220
– fundername: Graduate Education and Teaching Research and Reform Project of Tianjin University of Technology
  grantid: YBXM2321
GroupedDBID ---
53G
5VS
8G5
AADQD
AAYXX
ABDBF
ABUWG
ACGFO
ACIHN
ACUHS
AEAQA
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AZQEC
BENPR
BPHCQ
CCPQU
CITATION
DIK
DWQXO
EBD
ESX
F5P
FD6
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HH5
HYE
IAO
IHR
ITC
KQ8
M2O
MK0
MODMG
M~E
OK1
P6G
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RNS
RPM
TR2
TUS
NPM
3V.
7XB
8FK
M48
MBDVC
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c391t-57fc799e76253b478d0fbaf89100ac14159445fd85ab9c068975b9951f0d30423
IEDL.DBID DOA
ISSN 1999-4923
IngestDate Wed Aug 27 01:30:10 EDT 2025
Thu Aug 21 18:34:36 EDT 2025
Wed Jul 30 23:53:46 EDT 2025
Fri Jul 25 18:48:53 EDT 2025
Wed Aug 06 19:42:03 EDT 2025
Tue Aug 05 03:50:58 EDT 2025
Sun Aug 03 01:50:19 EDT 2025
Thu Jul 24 02:13:50 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords temozolomide
myricetin
tabletability
drug-drug cocrystal
dissolution
crystal structure
stability
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c391t-57fc799e76253b478d0fbaf89100ac14159445fd85ab9c068975b9951f0d30423
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
These authors contributed equally to this work.
OpenAccessLink https://doaj.org/article/b182103763ab4b50a5c28650394c7903
PMID 40733114
PQID 3233240479
PQPubID 2032349
ParticipantIDs doaj_primary_oai_doaj_org_article_b182103763ab4b50a5c28650394c7903
pubmedcentral_primary_oai_pubmedcentral_nih_gov_12299715
proquest_miscellaneous_3234705108
proquest_journals_3233240479
gale_infotracmisc_A849975004
gale_infotracacademiconefile_A849975004
pubmed_primary_40733114
crossref_primary_10_3390_pharmaceutics17070906
PublicationCentury 2000
PublicationDate 20250713
PublicationDateYYYYMMDD 2025-07-13
PublicationDate_xml – month: 7
  year: 2025
  text: 20250713
  day: 13
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Pharmaceutics
PublicationTitleAlternate Pharmaceutics
PublicationYear 2025
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Siegelin (ref_21) 2009; 454
Spackman (ref_33) 2009; 11
Jatyan (ref_13) 2022; 350
Deng (ref_5) 2017; 104
ref_14
Trask (ref_8) 2007; 4
Pop (ref_27) 2017; 1141
Laszcz (ref_34) 2013; 18
ref_35
Krishna (ref_38) 2015; 15
Thakuria (ref_3) 2013; 453
ref_10
Thipparaboina (ref_9) 2016; 21
ref_30
Wang (ref_11) 2021; 16
Park (ref_28) 2016; 59
Babu (ref_15) 2012; 7
Attari (ref_17) 2017; 23
Zhao (ref_24) 2018; 17
Hiendrawan (ref_6) 2016; 497
Wang (ref_19) 2021; 21
Aitipamula (ref_1) 2012; 12
Chattoraj (ref_37) 2010; 12
Li (ref_18) 2018; 18
Perumalla (ref_36) 2012; 14
Ren (ref_32) 2019; 9
Schultheiss (ref_2) 2009; 9
ref_20
Wang (ref_25) 2015; 124
Hammond (ref_16) 1999; 17
Karachi (ref_12) 2018; 20
ref_29
Zhu (ref_22) 2024; 20
Li (ref_26) 2020; 72
Lowe (ref_31) 1992; 35
Dai (ref_7) 2023; 647
ref_4
Song (ref_23) 2020; 38
References_xml – ident: ref_30
– ident: ref_20
  doi: 10.3390/pharmaceutics14010116
– volume: 18
  start-page: 4270
  year: 2018
  ident: ref_18
  article-title: Constructing anti-glioma drug combination with optimized properties through cocrystallization
  publication-title: Cryst. Growth Des.
  doi: 10.1021/acs.cgd.8b00807
– volume: 14
  start-page: 2389
  year: 2012
  ident: ref_36
  article-title: Ionized form of acetaminophen with improved compaction properties
  publication-title: CrystEngComm
  doi: 10.1039/C1CE06278F
– volume: 59
  start-page: 259
  year: 2016
  ident: ref_28
  article-title: Myricetin: Biological activity related to human health
  publication-title: Appl. Biol. Chem.
  doi: 10.1007/s13765-016-0150-2
– volume: 11
  start-page: 19
  year: 2009
  ident: ref_33
  article-title: Hirshfeld surface analysis
  publication-title: CrystEngComm
  doi: 10.1039/B818330A
– volume: 497
  start-page: 106
  year: 2016
  ident: ref_6
  article-title: Physicochemical and mechanical properties of paracetamol cocrystal with 5-nitroisophthalic acid
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2015.12.001
– volume: 20
  start-page: 494
  year: 2024
  ident: ref_22
  article-title: Morin Inhibits Cell Proliferation and Induces Caspase-mediated Apoptotic Cell Death in Glioma C6 Cell Line
  publication-title: Pharmacogn. Mag.
  doi: 10.1177/09731296231216828
– volume: 12
  start-page: 2147
  year: 2012
  ident: ref_1
  article-title: Polymorphs, salts, and cocrystals: What’s in a name?
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg3002948
– volume: 21
  start-page: 481
  year: 2016
  ident: ref_9
  article-title: Multidrug co-crystals: Towards the development of effective therapeutic hybrids
  publication-title: Drug Discov. Today
  doi: 10.1016/j.drudis.2016.02.001
– volume: 20
  start-page: 1566
  year: 2018
  ident: ref_12
  article-title: Temozolomide for immunomodulation in the treatment of glioblastoma
  publication-title: Nruro. Oncol.
  doi: 10.1093/neuonc/noy072
– ident: ref_14
– ident: ref_35
– volume: 15
  start-page: 1827
  year: 2015
  ident: ref_38
  article-title: Correlation among crystal structure, mechanical behavior, and tabletability in the co-crystals of vanillin isomers
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg5018642
– volume: 23
  start-page: 1841
  year: 2017
  ident: ref_17
  article-title: Temozolomide and its stability-a critical factor
  publication-title: Adv. Sci. Lett.
  doi: 10.1166/asl.2017.8486
– volume: 104
  start-page: 255
  year: 2017
  ident: ref_5
  article-title: Dapagliflflozin-citric acid cocrystal showing better solid state properties than dapagliflflozin
  publication-title: Eur. J. Pharm. Sci.
  doi: 10.1016/j.ejps.2017.04.008
– volume: 18
  start-page: 15344
  year: 2013
  ident: ref_34
  article-title: Identification and physicochemical characteristics of temozolomide process-related impurities
  publication-title: Molecules
  doi: 10.3390/molecules181215344
– volume: 453
  start-page: 101
  year: 2013
  ident: ref_3
  article-title: Pharmaceutical cocrystals and poorly soluble drugs
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2012.10.043
– volume: 17
  start-page: 557
  year: 2018
  ident: ref_24
  article-title: A multi-targeted natural flavonoid myricetin suppresses lamellipodia and focal adhesions formation and impedes glioblastoma cell invasiveness and abnormal motility
  publication-title: CNS Neurol. Disord. Drug Targets
  doi: 10.2174/1871527317666180611090006
– volume: 9
  start-page: 59
  year: 2019
  ident: ref_32
  article-title: The effects of pH, surfactant, ion concentration, coformer, and molecular arrangement on the solubility behavior of myricetin cocrystals
  publication-title: Acta Pharm. Sin. B
  doi: 10.1016/j.apsb.2018.09.008
– volume: 454
  start-page: 223
  year: 2009
  ident: ref_21
  article-title: Daidzein overcomes TRAIL-resistance in malignant glioma cells by modulating the expression of the intrinsic apoptotic inhibitor, bcl-2
  publication-title: Neurosci. Lett.
  doi: 10.1016/j.neulet.2009.03.031
– ident: ref_29
– volume: 12
  start-page: 2466
  year: 2010
  ident: ref_37
  article-title: Understanding the relationship between crystal structure, plasticity and compaction behavior of theophylline, methyl gallate, and their 1:1 co-crystal
  publication-title: CrystEngComm
  doi: 10.1039/c000614a
– volume: 647
  start-page: 123497
  year: 2023
  ident: ref_7
  article-title: Improving the physicochemical and pharmacokinetic properties of olaparib through cocrystallization strategy
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2023.123497
– volume: 124
  start-page: 5
  year: 2015
  ident: ref_25
  article-title: Effect of treatment with baicalein on the intracerebral tumor growth and survival of orthotopic glioma models
  publication-title: J. Neuro-Oncol.
  doi: 10.1007/s11060-015-1804-3
– volume: 9
  start-page: 2950
  year: 2009
  ident: ref_2
  article-title: Pharmaceutical Cocrystals and Their Physicochemical Properties
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg900129f
– ident: ref_10
  doi: 10.3390/pharmaceutics17050678
– volume: 4
  start-page: 301
  year: 2007
  ident: ref_8
  article-title: An overview of pharmaceutical cocrystals as intellectual property
  publication-title: Mol. Pharm.
  doi: 10.1021/mp070001z
– volume: 72
  start-page: 538
  year: 2020
  ident: ref_26
  article-title: Hesperetin induces apoptosis in human glioblastoma cells via p38 MAPK activation
  publication-title: Nutr. Cancer
  doi: 10.1080/01635581.2019.1638424
– volume: 1141
  start-page: 607
  year: 2017
  ident: ref_27
  article-title: Solid dispersions of Myricetin with enhanced solubility: Formulation, characterization and crystal structure of stability-impeding Myricetin monohydrate crystals
  publication-title: J. Mol. Struct.
  doi: 10.1016/j.molstruc.2017.04.015
– volume: 17
  start-page: 2604
  year: 1999
  ident: ref_16
  article-title: Phase I and pharmacokinetic study of Temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.1999.17.8.2604
– volume: 35
  start-page: 3377
  year: 1992
  ident: ref_31
  article-title: Antitumor imidazotetrazines. 25. Crystal structure of 8-carbamoyl-3-methylimidazo [5, 1-d]-1, 2, 3, 5-tetrazin-4 (3H)-one (temozolomide) and structural comparisons with the related drugs mitozolomide and DTIC
  publication-title: J. Med. Chem.
  doi: 10.1021/jm00096a013
– volume: 7
  start-page: 2274
  year: 2012
  ident: ref_15
  article-title: Crystal engineering of stable temozolomide cocrystals
  publication-title: Chem.–Asian J.
  doi: 10.1002/asia.201200205
– volume: 21
  start-page: 838
  year: 2021
  ident: ref_19
  article-title: Temozolomide–hesperetin drug–drug cocrystal with optimized performance in stability, dissolution, and tabletability
  publication-title: Cryst. Growth Des.
  doi: 10.1021/acs.cgd.0c01153
– volume: 38
  start-page: 1743
  year: 2020
  ident: ref_23
  article-title: Glioma progression is suppressed by Naringenin and APO2L combination therapy via the activation of apoptosis in vitro and in vivo
  publication-title: Investig. New Drugs
  doi: 10.1007/s10637-020-00979-2
– volume: 350
  start-page: 494
  year: 2022
  ident: ref_13
  article-title: Polymeric and small molecule-conjugates of temozolomide as improved therapeutic agents for glioblastoma multiforme
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2022.08.024
– ident: ref_4
  doi: 10.3390/pharmaceutics17030371
– volume: 16
  start-page: 307
  year: 2021
  ident: ref_11
  article-title: Drug-drug cocrystals: Opportunities and challenges
  publication-title: Asian J. Pharm. Sci.
SSID ssj0000331839
Score 2.345096
Snippet Objectives: Drug-drug cocrystals with improved properties can be used to facilitate the development of synergistic therapeutic combinations. The goal of the...
: Drug-drug cocrystals with improved properties can be used to facilitate the development of synergistic therapeutic combinations. The goal of the present...
Objectives : Drug-drug cocrystals with improved properties can be used to facilitate the development of synergistic therapeutic combinations. The goal of the...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 906
SubjectTerms Crystal structure
Crystals
Data collection
Diffraction
Drug therapy
drug-drug cocrystal
Drugs
Flavonoids
Fourier transforms
Glioma
Gliomas
Health aspects
Humidity
Hydrogen
Hydrogen bonding
Infrared spectroscopy
myricetin
Pharmaceuticals
Physicochemical properties
Radiation
Software
Spectrum analysis
stability
Structure
tabletability
Temozolomide
X-rays
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Nb5swFLe29rLLtO_RdpMnTd0lrAbbAe8ypVmqalIjNKVSbwgbk0ZqISOkUvrX7z0gJGjTLjnYJmDe98Pv9wj5zLiVKbPaTX1fuSJVgQuxSuhmWvAEHFTP1GdzrqbDy2vx80betAm3VXuscqsTa0WdFgZz5Gfc54gdJwL1ffnbxa5R-HW1baHxlByCCg4h-Do8n0yjX12WhXHkWdWU7nCI78-Wt7tU8coLgOMVdjvaM0o1dv_fGnrPRPWPT-7Zo4sX5HnrSNJRQ_mX5InNX5HTqLnvZkBnu8Kq1YCe0miHUb15TeYjOi0e7B2d2fviEQbvF6l1rzYIMVQtcvqjXM9d_KHjwpQbcCHvvtGotA1SeJEP6LhDen5sRyLM65fVhk46BPHVG3J9MZmNL92254JruPIqVwaZCZSyoCMl1yIIU5bpJAvBq2CJ8cDcKyFkloYy0cqwYagCqRW4aRlLMTPC35KDvMjte0LBNApruZZMG-Epk4S-SRWWbEtQFGzokK_blx4vG2iNGEISpFL8Tyo55BxJ0y1GZOx6oCjncStosYaACWsfhzzRAu6dSIPFt4wrARtj3CFfkLAxyi9QzyRtGQI8MyJhxaMQYkBwo5hwyElvJcid6U9vWSNu5X4V77jUIZ-6abwSz7LltljXa0SAujB0yLuGk7otibqHpgd_HvZ4rLfn_ky-uK1RwT0QNhV48uj_z3VMnvnYwhixQfkJOajKtf0AflWlP7bC8wdERSQh
  priority: 102
  providerName: ProQuest
Title A Novel Temozolomide-Myricetin Drug-Drug Cocrystal: Preparation, Characterization, Property Evaluations
URI https://www.ncbi.nlm.nih.gov/pubmed/40733114
https://www.proquest.com/docview/3233240479
https://www.proquest.com/docview/3234705108
https://pubmed.ncbi.nlm.nih.gov/PMC12299715
https://doaj.org/article/b182103763ab4b50a5c28650394c7903
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Na9swFBeju-wytu7LXVs0GN0lXmVLiq3d0iylDBrMSKE3Y8lyG2jt4jgD96_fe7br2Gywyy4-SLIt6X0Lvd8j5DPjVqbMajf1feWKVAUuxCqhm2nBE3BQPdPczblcTi-uxI9reT0o9YV3wlp44HbjTjU4wJjLNuWJFlqyRBpMpmRcCROoFucTbN4gmGp0MEdeVW3KDoe4_vThdndEvPEC4HSFVY4GxqjB7P9TMw9M0_ja5MAOnb8iLzsHks7aib8mz2y-T06i9r_1hK52CVWbCT2h0Q6bun5DbmZ0Wfyyd3Rl74tHaLxfp9a9rBFaqFrn9Hu5vXHxQeeFKWtwHe--0ai0LUJ4kU_ovEd4fuxaIjzPL6uaLnrk8M1bcnW-WM0v3K7Wgmu48ipXBhlsp7KgGyXXIghTlukkC8GbYInxwMwrIWSWhjLRyrBpqAKpFbhnGUvxRIS_I3t5kdsPhIJJFNZyoJU2wlMmCX2TKkzVlqAg2NQhX582PX5oITViCEWQSvFfqeSQMyRNPxgRsZsG4JO445P4X3zikC9I2BjlFqhnki79AOaMCFjxLITYD9wnJhxyOBoJ8mbG3U-sEXfyvom5zxHZUATKIZ_6bnwT77Dlttg2Y0SAOjB0yPuWk_oliaZ2pgcfD0c8NlrzuCdf3zZo4B4ImQo8efA_dukjeeFjgWNEDuWHZK8qt_YIvK5KH5PnZ4tl9PO4EbTfz9sq-g
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3Nb9MwFLdGd4AL4pvAACPBuDTMiZ0mRkKo6zp1bK0q1Em7hcRxukpbUtIWlP1R_I28l6RpIxC3XXKwncTO-3b8fo-Qd4xrJ2I6NCPblqaIpGtCrOKZcSh4AA6qpYqzOcNRZ3Auvl44Fzvk9zoXBo9VrnVioaijVOEe-QG3OWLHCVd-mf8wsWoU_l1dl9Ao2eJU578gZFt8PjkC-r637eP-pDcwq6oCpuLSWpqOGytXSg1awOGhcL2IxWEQe2A3WaAsMGhSCCeOPCcIpWIdT7pOKMERiVmEsT-H594hu4JDKNMiu4f90fhbvavDOMqILFOFOJfsYH652ZpeWC5ImMTqSltGsKgV8LdF2DKJzeOaW_bv-AG5XzmutFty2kOyo5NHZH9cvjdv08kmkWvRpvt0vMHEzh-TaZeO0p_6ik70dXoDjdezSJvDHCGNlrOEHmWrqYkX2ktVloPLevWJjjNdIpOnSZv2amTpm6pljP8RsmVO-zVi-eIJOb8VajwlrSRN9HNCwRQLrXnosFAJS6rAs1UkMUXcAcXEOgb5uP7o_ryE8vAhBEIq-f-kkkEOkTT1YETiLhrSbOpXgu2HEKBhrmWHB6GAdweOwmRfxqWAhTFukA9IWB_1BVBPBVXaA8wZkbf8rgcxJ7htTBhkrzES5Fw1u9es4Vd6ZuFvpMIgb-tuvBPPziU6XRVjhIu61zPIs5KT6iWJomanBQ_3GjzWWHOzJ5ldFijkFgi3dC3nxf_n9YbcHUyGZ_7Zyej0JblnY_lkxCXle6S1zFb6Ffh0y_B1JUiUfL9t2f0D0JdfGg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJyFeEHcCA4wE46VZndhpYiSEunbVxlhVoU7aW0gcp6u0JSVtQdlP49dxTpKmjUC87aUPtnNxz9055zuEvGNcOxHToRnZtjRFJF0TYhXPjEPBA3BQLVXk5pyNusfn4suFc7FDfq9rYTCtcq0TC0UdpQrPyDvc5ogdJ1zZiau0iPFg-Hn-w8QOUvildd1Oo2SRU53_gvBt8elkALR-b9vDo0n_2Kw6DJiKS2tpOm6sXCk1aASHh8L1IhaHQeyBDWWBssC4SSGcOPKcIJSKdT3pOqEEpyRmEZ4DcLjvHbLrQlTEWmT38Gg0_laf8DCO8iLLsiHOJevMLzfH1AvLhYskdlraMohF34C_rcOWeWymbm7ZwuEDcr9yYmmv5LqHZEcnj8j-uHxu3qaTTVHXok336XiDj50_JtMeHaU_9RWd6Ov0BgavZ5E2z3KEN1rOEjrIVlMTf2g_VVkO7uvVRzrOdIlSniZt2q9Rpm-qkTF-U8iWOT2q0csXT8j5rVDjKWklaaKfEwpmWWjNQ4eFSlhSBZ6tIonl4g4oKdY1yMH6T_fnJayHD-EQUsn_J5UMcoikqRcjKncxkGZTvxJyP4RgDesuuzwIBTw7cBQW_jIuBWyMcYN8QML6qDuAeiqoSiDgnRGFy-95EH-CC8eEQfYaK0HmVXN6zRp-pXMW_kZCDPK2nsYrMY8u0emqWCNc1MOeQZ6VnFRvSRT9Oy24udfgscaemzPJ7LJAJLdA0KVrOS_-_15vyF2QWf_ryej0JblnYydlhCjle6S1zFb6Fbh3y_B1JUeUfL9t0f0DKdhjTw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Novel+Temozolomide-Myricetin+Drug-Drug+Cocrystal%3A+Preparation%2C+Characterization%2C+Property+Evaluations&rft.jtitle=Pharmaceutics&rft.au=Hai-Xin+Qin&rft.au=Jie+Wang&rft.au=Jia-Hui+Peng&rft.au=Xia-Lin+Dai&rft.date=2025-07-13&rft.pub=MDPI+AG&rft.eissn=1999-4923&rft.volume=17&rft.issue=7&rft.spage=906&rft_id=info:doi/10.3390%2Fpharmaceutics17070906&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_b182103763ab4b50a5c28650394c7903
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1999-4923&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1999-4923&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1999-4923&client=summon